Targeting KAT7 inhibits the progression of colorectal cancer
Hao Wang, Tianwang Guan, Rong Hu, Zhongjie Huang, Liang Zhao, Xiaonan Lin, Yingqi Qiu, Peiyun Liao, Xiongbo Guo, Yushen Ke, Honghao Zhang, Caiwen Ou, Yuhua Li
Abstract
We found that KAT7 is highly expressed in CRC patients, and those with high KAT7 expression have a worse prognosis. KAT7 enhances MRAS gene transcription by promoting H3K14 acetylation, thereby activating the MAPK/ERK pathway and promoting malignant phenotypes of CRC. In summary, KAT7 represents a promising target for CRC therapy.
Topics & Concepts
Colorectal cancerCancer researchMedicineCancerOncologyInternal medicineCancer Genomics and DiagnosticsEpigenetics and DNA MethylationCancer-related gene regulation